Tags

Type your tag names separated by a space and hit enter

[Repeat midurethral sling for female stress urinary incontinence after failure of the initial sling].
Prog Urol. 2009 Oct; 19(9):590-4.PU

Abstract

OBJECTIVE

Midurethral sling (MUS) is the gold standard treatment of female stress urinary incontinence (SUI). No consensus exists regarding the way to manage patients who have persistent or recurrent SUI following MUS. The aim was to evaluate the use of a second MUS for the treatment of persistent or recurrent SUI following a first MUS.

METHODS

Literature review based on keywords: "stress urinary incontinence", "tape", "failure", "second MUS".

RESULTS

Fifty-one cases of second MUS were identified within five studies. No major complication was reported. The success rate of second MUS ranged from 76 to 100% with a median follow-up of 5 to 22 months. The use of a retropubic approach for the repeat MUS could be more efficient than the transobturator way.

CONCLUSION

The repeat MUS for persistent or recurrent SUI appears to be a safe and efficient therapeutic option. Further studies with larger number of patients and longer follow-up are needed to reach definite conclusions.

Authors+Show Affiliations

Service d'Urologie, Hôpital Cochin-Port-Royal, Paris, France. evanguelosxylinas@hotmail.comNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

19800546

Citation

Xylinas, E, and A Descazeaud. "[Repeat Midurethral Sling for Female Stress Urinary Incontinence After Failure of the Initial Sling]." Progres En Urologie : Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie, vol. 19, no. 9, 2009, pp. 590-4.
Xylinas E, Descazeaud A. [Repeat midurethral sling for female stress urinary incontinence after failure of the initial sling]. Prog Urol. 2009;19(9):590-4.
Xylinas, E., & Descazeaud, A. (2009). [Repeat midurethral sling for female stress urinary incontinence after failure of the initial sling]. Progres En Urologie : Journal De l'Association Francaise D'urologie Et De La Societe Francaise D'urologie, 19(9), 590-4. https://doi.org/10.1016/j.purol.2009.04.012
Xylinas E, Descazeaud A. [Repeat Midurethral Sling for Female Stress Urinary Incontinence After Failure of the Initial Sling]. Prog Urol. 2009;19(9):590-4. PubMed PMID: 19800546.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Repeat midurethral sling for female stress urinary incontinence after failure of the initial sling]. AU - Xylinas,E, AU - Descazeaud,A, Y1 - 2009/06/03/ PY - 2009/03/05/received PY - 2009/04/01/revised PY - 2009/04/27/accepted PY - 2009/10/6/entrez PY - 2009/10/6/pubmed PY - 2009/12/16/medline SP - 590 EP - 4 JF - Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie JO - Prog Urol VL - 19 IS - 9 N2 - OBJECTIVE: Midurethral sling (MUS) is the gold standard treatment of female stress urinary incontinence (SUI). No consensus exists regarding the way to manage patients who have persistent or recurrent SUI following MUS. The aim was to evaluate the use of a second MUS for the treatment of persistent or recurrent SUI following a first MUS. METHODS: Literature review based on keywords: "stress urinary incontinence", "tape", "failure", "second MUS". RESULTS: Fifty-one cases of second MUS were identified within five studies. No major complication was reported. The success rate of second MUS ranged from 76 to 100% with a median follow-up of 5 to 22 months. The use of a retropubic approach for the repeat MUS could be more efficient than the transobturator way. CONCLUSION: The repeat MUS for persistent or recurrent SUI appears to be a safe and efficient therapeutic option. Further studies with larger number of patients and longer follow-up are needed to reach definite conclusions. SN - 1166-7087 UR - https://www.unboundmedicine.com/medline/citation/19800546/[Repeat_midurethral_sling_for_female_stress_urinary_incontinence_after_failure_of_the_initial_sling]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1166-7087(09)00137-7 DB - PRIME DP - Unbound Medicine ER -